Neuropathy News and Research RSS Feed - Neuropathy News and Research

Study reveals association between DNA methylation and type 2 diabetes

Study reveals association between DNA methylation and type 2 diabetes

Researchers from the Hospital del Mar Medical Research Institute have found an epigenetic mechanism implicated in the regulation of blood sugar. The study, published in the journal Molecular Human Genetics, reveals that the methylation of the TXNIP gene is associated with diabetes mellitus type 2 and, in particular, average blood glucose levels. [More]
RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has completed enrollment of its Phase 2b/3 dry eye trial in the U.S. [More]
Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. [More]
Halaven (eribulin mesylate) approved for treatment of liposarcoma

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. [More]
Researchers developing cryotherapy device to reduce tissue damage

Researchers developing cryotherapy device to reduce tissue damage

Cold therapy has long been prescribed for those recovering from orthopedic surgery, muscle inflammation and sports-related injuries, with treatments ranging from ice baths to immersion in whole-body cryotherapy chambers. [More]
Educational programs, new clinic policies could significantly reduce level of opioid medication

Educational programs, new clinic policies could significantly reduce level of opioid medication

A recent study showed that medical provider training, new clinic policies and efforts to "taper" opioid use for pain treatment could significantly reduce the level of opioid medication that patients used -- a limited but positive step for a nation enmeshed in opioid use, abuse and overdose deaths. [More]
Opioid medication does not improve physical function in patients with neuropathic pain

Opioid medication does not improve physical function in patients with neuropathic pain

Opioids such as morphine, codeine and Tylenol 3 can be effective for treating pain, however, a new University of Alberta study finds that patients with neuropathic pain taking opioids report no improvements in physical functioning compared to those who were not prescribed opioids. [More]
Acute bulbar palsy variant of Guillain-Barré syndrome found

Acute bulbar palsy variant of Guillain-Barré syndrome found

Researchers have identified a new variant form of Guillain-Barré syndrome that is characterised by prominent acute bulbar palsy without neck or limb weakness. [More]
Araim Pharmaceuticals forms new strategic collaboration with Vault Bioventures to market novel peptides

Araim Pharmaceuticals forms new strategic collaboration with Vault Bioventures to market novel peptides

Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies. [More]
Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research Inc., a life sciences company with growing revenues and a diverse portfolio of topical products, today announced the results of its investigational Phase 2 clinical trial of WF10 (Trial) for the treatment of allergic rhinitis. [More]
Role for carfilzomib in relapsed, refractory multiple myeloma treatment

Role for carfilzomib in relapsed, refractory multiple myeloma treatment

Carfilzomib significantly improves outcomes in previously treated patients with relapsed or refractory multiple myeloma, shows a head-to-head comparison with bortezomib. [More]
Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma. [More]
FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. [More]
Ninlaro (ixazomib) approved to treat people with multiple myeloma

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy. [More]
Global tissue engineered medical devices market expected to cross US$ 26 billion by 2020

Global tissue engineered medical devices market expected to cross US$ 26 billion by 2020

According to recently published Pharmaion report, "Global Tissue Engineered Medical Devices Market Forecast & Opportunities, 2020", global tissue engineered medical devices market is anticipated to cross US$ 26 billion by 2020. [More]
MedUni Vienna researchers discover genetic cause of a rare disease

MedUni Vienna researchers discover genetic cause of a rare disease

Researchers at MedUni Vienna have discovered the genetic cause of a rare disease characterized by life-threatening "liver crises" in early childhood and subsequent manifestation of neurological symptoms, such as neuropathy and ataxia (a movement disorder), when they reach school age. [More]
Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis). [More]
United Cannabis files utility and PCT patent applications related to unique specifications of cannabinoids

United Cannabis files utility and PCT patent applications related to unique specifications of cannabinoids

United Cannabis Corporation today announced that it moved its provisional patent application to the next phase by filing a utility patent application related to the unique combinations of pharmaceutically active cannabinoids used to treat disorders of the nervous system, immune system and cancer with the U.S. Patent and Trademark Office. [More]
University of Arkansas biomedical engineer awarded NIH grant to study chronic wound biomarkers

University of Arkansas biomedical engineer awarded NIH grant to study chronic wound biomarkers

The National Institutes of Health awarded a University of Arkansas biomedical engineer a new $744,992 grant to improve imaging and early detection of chronic wounds and guide treatments. [More]
New study from TSRI and Salk points to cause of debilitating nerve disease

New study from TSRI and Salk points to cause of debilitating nerve disease

Scientists at The Scripps Research Institute (TSRI) and the Salk Institute for Biological Studies have discovered how a mutant protein triggers nerve damage in a subtype of Charcot-Marie-Tooth (CMT) diseases, a group of currently untreatable conditions that cause loss of function in a person’s hands and feet. [More]
Advertisement
Advertisement